Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.17

Massimo

13.84

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

136.6

56.432

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.11% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

462M

2.4B

Apertura precedente

13.61

Chiusura precedente

13.61

Notizie sul Sentiment di mercato

By Acuity

50%

50%

125 / 339 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2026, 23:56 UTC

Event
News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

17 set 2026, 23:41 UTC

News
Correlated Moves

Starwood Property Trust Inc announced a quarterly dividend of $0.48 per share, with shares moving higher in after-market trading following the announcement.

17 set 2026, 23:41 UTC

News
Correlated Moves
Macro Event

USD/HUF exchange rate is declining amid mixed macroeconomic signals, including a drop in U.S. initial jobless claims and weaker housing data.

17 set 2026, 23:26 UTC

News

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

17 set 2026, 23:16 UTC

News

Leonardo DRS, Inc. is higher in after-market trading following a contract with Doosan Enerbility to supply propulsion systems for South Korea's KDDX destroyer program.

17 set 2026, 23:16 UTC

News

Modine Manufacturing announces key merger dates and terms with Gentherm, including a $1.90 special cash dividend, as shares trade higher in after-market hours.

17 set 2026, 23:11 UTC

News

Cooper Companies shares are higher in after-market trading following insider purchases totaling $549K, despite calls for major changes from Jana Partners.

17 set 2026, 23:11 UTC

News

Enterprise Financial Services Corp shares declined in after-market trading following an Equal Weight rating initiation by Stephens analyst Brandon Rud.

17 set 2026, 23:11 UTC

News

Hercules Capital appointed Alfred B. Fichera to its Board of Directors, effective September 17, 2026, with stock trading modestly higher in after-market hours.

17 set 2026, 23:06 UTC

Social Media
News

Ultragenyx Pharmaceutical Inc. gained FDA approval for Fayuvi, the first gene therapy for Sanfilippo syndrome type A, driving after-market trading higher.

17 set 2026, 23:06 UTC

News

Coinbase Global Inc. shares are modestly lower in after-market trading as CEO Brian Armstrong declares the Clarity Act likely "dead" and explores alternative regulatory paths.

17 set 2026, 23:06 UTC

News

Twist Bioscience Corp's stock rises after a partnership with Eli Lilly's TuneLab, with Leerink raising its price target to $160 and increased fiscal 2026 sales guidance.

17 set 2026, 23:06 UTC

News
Correlated Moves
Macro Event

USD/SGD exchange rate is experiencing a slight decline, remaining roughly flat since Wednesday, amid mixed macroeconomic data impacting market sentiment.

17 set 2026, 23:06 UTC

Correlated Moves
News

The USD/CZK is trading lower, reflecting routine price movement despite recent strength, with little change since Wednesday's close.

17 set 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

17 set 2026, 23:01 UTC

News
Event

Nucor Corporation's after-market shares declined following third-quarter earnings guidance of $5.55 to $5.65 per share, below the consensus estimate of $6.20.

17 set 2026, 23:01 UTC

News

Walt Disney Co's stock is modestly higher in after-market trading following leadership changes aimed at enhancing its direct-to-consumer offerings.

17 set 2026, 23:01 UTC

News
Correlated Moves

Rithm Capital Corp declared a quarterly dividend of $0.25 per share, with the stock advancing in after-market trading following the announcement.

17 set 2026, 23:01 UTC

News

Campbell's Company extended the maturity date of its $1.85 billion credit agreement to April 16, 2031, and is modestly higher in after-market trading.

17 set 2026, 22:11 UTC

News

WBD's stock is trading modestly higher in after-market hours following FCC approval of foreign funding for the Paramount merger, enhancing operational synergies.

17 set 2026, 22:02 UTC

News

Agree Realty Corporation has priced $400 million in senior unsecured notes to enhance liquidity, with shares modestly higher in after-market trading.

17 set 2026, 22:01 UTC

Event
News

Steel Dynamics Inc issued Q3 2026 earnings guidance of $5.34 to $5.38 per share, below the $5.60 consensus, contributing to a decline in after-market trading.

17 set 2026, 21:31 UTC

News

BRT Apartments Corp. declared a $0.25 quarterly dividend and approved a $10 million share repurchase program, leading to gains in after-market trading.

17 set 2026, 20:31 UTC

News

Hub Group, Inc. declined in after-market trading following a Nasdaq delisting determination due to failure to file required reports, marking its lowest point since Thursday's close.

17 set 2026, 20:08 UTC

News

Shares of Scholar Rock Holding Corp fell modestly as the stock continues a five-session decline, despite FDA approval for its ISEMBYLD treatment.

17 set 2026, 20:08 UTC

Social Media
News

Dell Technologies Inc's market capitalization increased by $105 billion over 11 days, with the stock advancing today amid speculation of a price target of $630.

17 set 2026, 20:08 UTC

News
Correlated Moves
Social Media

Shares of Advanced Micro Devices advanced today on reports of planned price increases for GPUs and CPUs due to rising wafer costs from TSMC.

17 set 2026, 20:08 UTC

Correlated Moves
News

Cloudflare Inc. shares are higher today following Bernstein SocGen's price target increase, despite pulling back from a session high earlier.

17 set 2026, 20:08 UTC

News

Rivian's stock is trading higher as call volume reaches 27.1k contracts, indicating strong demand ahead of its earnings report on November 3rd.

17 set 2026, 20:08 UTC

Correlated Moves
Social Media
News

Marvell Technology's shares are advancing as it expands its agreement with GlobalFoundries to enhance silicon germanium capacity amid rising demand for optical connectivity products.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

20.11% in crescita

Previsioni per 12 mesi

Media 16.167 USD  20.11%

Alto 18.5 USD

Basso 14 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

125 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.